PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30535690-5	2019	Using these protocols, we recently detected a metabolic alteration that occurs during aging by the monitoring the lactate/pyruvate ratio in a long-lived mutant of the mammalian tumor suppressor p53 ortholog CEP-1 in C. elegans.	Pyruvic Acid	122-130	tumor protein p53	Homo sapiens	194-197	
24275138-4	2014	p53 Silencing decreased survival of glucose-starved C8161 melanoma with pyruvate supplementation under hypoxia (<=1% oxygen), but increased resistance to glycolytic inhibitors oxamate and 2-deoxyglucose in 5mM glucose, preferentially under normoxia.	Pyruvic Acid	72-80	tumor protein p53	Homo sapiens	0-3	
24486524-8	2014	CONCLUSIONS: (a) ERalpha(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ERalpha(+) breast cancer with p53 dysfunction.	Pyruvic Acid	254-262	tumor protein p53	Homo sapiens	66-70	
24275138-1	2014	We demonstrated that exogenous pyruvate promotes survival under glucose depletion in aerobic mutant p53 (R175H) human melanoma cells.	Pyruvic Acid	31-39	tumor protein p53	Homo sapiens	100-103	
21832879-0	2011	Metabolic utilization of exogenous pyruvate by mutant p53 (R175H) human melanoma cells promotes survival under glucose depletion.	Pyruvic Acid	35-43	tumor protein p53	Homo sapiens	54-57	
21832879-6	2011	Metabolic utilization and survival under glucose depletion was increased by pyruvate in mutant p53 (R175H) cells.	Pyruvic Acid	76-84	tumor protein p53	Homo sapiens	95-98	
21832879-7	2011	Our results show for the first time that melanoma cells harbouring a p53 (R175H) mutation increase: a) survival under glucose depletion, counteracted by NADPH-oxidase modulators like DPI; b) resistance to DPI when supplemented with exogenous pyruvate.	Pyruvic Acid	242-250	tumor protein p53	Homo sapiens	69-72	
12935767-8	2003	The induction and nuclear translocation of p53 by H2O2 was blocked by pyruvate and appeared to be somewhat enhanced by L-lactate or aminooxyacetate in association with oxidant generation.	Pyruvic Acid	70-78	tumor protein p53	Homo sapiens	43-46	
14578369-1	2004	We recently reported that pyruvate inhibited translocation and activation of p53 caused by DNA damage due to oxidant injury (Lee YJ, Kang IJ, Bunger R, and Kang YH.	Pyruvic Acid	26-34	tumor protein p53	Homo sapiens	77-80	
12935767-10	2003	The pyruvate-related redox manipulation inhibited the H2O2-induced p53 activation, restored the downregulated bcl-2 and the upregulated bax, and hence enhanced the bcl-2/bax expression ratio.	Pyruvic Acid	4-12	tumor protein p53	Homo sapiens	67-70	
12051701-2	2002	Fibroblasts treated with pyruvate undergo a rapid growth arrest accompanied by elevated levels of the cell-cycle regulatory molecules p53, p21, and p16.	Pyruvic Acid	25-33	tumor protein p53	Homo sapiens	134-137	
35189247-4	2022	Out of these, the most prominent genetic alterations (PRKAR-1A, CTNNB1, ZNRF3, TP53, CCNE1 and TERF2 genes) are linked with a glycolytic enzyme pyruvate kinase M2 (PKM2), which converts phosphoenolpyruvate (PEP) to pyruvate in the glycolytic pathway.	Pyruvic Acid	215-223	tumor protein p53	Homo sapiens	79-83